Last reviewed · How we verify
SHR1459 high-fat diet in P1, fasted in P2 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SHR1459 high-fat diet in P1, fasted in P2 (SHR1459 high-fat diet in P1, fasted in P2) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SHR1459 high-fat diet in P1, fasted in P2 TARGET | SHR1459 high-fat diet in P1, fasted in P2 | Jiangsu HengRui Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SHR1459 high-fat diet in P1, fasted in P2 CI watch — RSS
- SHR1459 high-fat diet in P1, fasted in P2 CI watch — Atom
- SHR1459 high-fat diet in P1, fasted in P2 CI watch — JSON
- SHR1459 high-fat diet in P1, fasted in P2 alone — RSS
Cite this brief
Drug Landscape (2026). SHR1459 high-fat diet in P1, fasted in P2 — Competitive Intelligence Brief. https://druglandscape.com/ci/shr1459-high-fat-diet-in-p1-fasted-in-p2. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab